- 4009 Hackney Springs Ln, Sachse, TX 75048
Key takeaways
Here’s a scene we see every month. A lab runs a clean, well-validated test. The result is accurate. The ordering physician is happy. Then the remittance comes back with a CO-11 or a CO-50, and the lab is out the reagent cost, the tech time and the payment.
Nothing was wrong with the science here. Something was wrong with the codes.
This guide walks through how laboratory coding actually works in 2027: which code sets you use, how the CPT Pathology and Laboratory section is built, the specialty rules that trip up even experienced billers, and the modifiers, edits and denial codes that decide whether you get paid. Each section links to a deeper guide if you want the full detail on one topic.
Laboratory coding is the work of assigning procedure codes, diagnosis codes and modifiers to each test a lab performs so it can be billed on a claim. It sounds like physician coding. In practice, it’s a different job.
A physician coder starts with an encounter: a visit, a history, an exam, a decision. A lab coder starts with a requisition. The lab almost never sees the patient. It receives a specimen, an order and, if it’s lucky, a diagnosis code that actually supports the test.
Four things make lab coding its own discipline:
Your CLIA certificate also limits what you can bill. A lab holding a Certificate of Waiver can’t bill moderate- or high-complexity tests, and a mismatch shows up as a CO-B7 denial. We cover that link in our guide to CLIA compliance and lab billing.
| Code set | Owner | Updates | What it describes | Lab example |
|---|---|---|---|---|
| CPT Category I | AMA | Annually, effective Jan 1 | The test or procedure | 80053 comprehensive metabolic panel |
| PLA codes (U codes) | AMA | Quarterly | One specific proprietary test from one lab or manufacturer | 0241U SARS-CoV-2, flu A/B and RSV assay |
| MAAA codes | AMA | Annually (Category I) and as needed (administrative M codes) | Algorithmic analyses that combine several results into a score | 81519 breast cancer recurrence score |
| HCPCS Level II | CMS | Quarterly | Services Medicare wants reported differently from CPT, plus supplies and travel | G0481 definitive drug testing, 8–14 drug classes |
| ICD-10-CM | CDC NCHS and CMS | Annually, effective Oct 1 (with occasional April updates) | Why the test was ordered | E11.9 type 2 diabetes without complications |
| CPT range | Subsection | What it covers |
|---|---|---|
| 80047–80081 | Organ or disease-oriented panels | Fixed groups of tests, such as BMP, CMP, lipid and hepatic panels. Every listed component must be performed. |
| 80143–80377 | Drug assay | Therapeutic drug levels, presumptive drug screening (80305–80307) and definitive drug testing (80320–80377) |
| 80400–80439 | Evocative/suppression testing | Stimulation and suppression protocols, with the drug supply and administration reported separately |
| 80503–80506 | Consultations (clinical pathology) | Pathologist consultations on clinical lab results, by time and complexity |
| 81000–81099 | Urinalysis | Dipstick and microscopic urinalysis, pregnancy tests on urine |
| 81105–81479 | Molecular pathology | Tier 1 gene-specific codes, Tier 2 resource-level codes (81400–81408), genomic sequencing procedures and the unlisted code 81479 |
| 81490–81599 | MAAA | Multianalyte assays with algorithmic analyses |
| 82009–84999 | Chemistry | Individual analytes, such as glucose, A1c, TSH and vitamin D, plus unlisted chemistry 84999 |
| 85002–85999 | Hematology and coagulation | CBCs, differentials, coagulation studies, bone marrow smear interpretation |
| 86000–86849 | Immunology | Antibody and antigen testing, autoimmune panels, HLA and allergen-specific testing |
| 86850–86999 | Transfusion medicine | Blood typing, antibody screens, crossmatches |
| 87003–87999 | Microbiology | Cultures, organism identification, susceptibility, antigen detection and nucleic acid amplification for infectious agents |
| 88000–88099 | Anatomic pathology | Postmortem examinations |
| 88104–88199 | Cytopathology | Pap tests, fine needle aspirates, body fluid cytology, flow cytometry (88184–88189) |
| 88230–88299 | Cytogenetic studies | Chromosome analysis, karyotyping and molecular cytogenetics (FISH by 88271–88275) |
| 88300–88399 | Surgical pathology | Gross and microscopic exam levels I–VI (88300–88309), special stains, IHC, frozen sections, in situ hybridization |
| 88720–88749 | In vivo laboratory procedures | Transcutaneous measurements such as bilirubin |
| 89049–89240 | Other procedures | Miscellaneous lab services such as sweat collection and gastric analysis |
| 89250–89398 | Reproductive medicine | Embryology and andrology procedures |
| 0001U and up | Proprietary Laboratory Analyses | Specific branded tests, released quarterly |
Molecular coding follows a hierarchy. Check for a PLA code first. If there isn’t one, look for a Tier 1 gene-specific code. For multi-gene panels, look for a genomic sequencing procedure (GSP) code. Only then consider Tier 2 (81400–81408) or, as a last resort, the unlisted code 81479.
Example: A hereditary breast cancer panel that meets the gene requirements of 81432 is reported with 81432. Billing each gene separately on its own Tier 1 code, when a panel code describes the test, is unbundling.
If your lab bills Medicare in a MolDX jurisdiction, coding is only half the job. MolDX, run by Palmetto GBA and followed by several MACs, requires most molecular tests to be registered in the DEX Diagnostics Exchange and assigned a Z-Code. Claims without the Z-Code are rejected or denied. Read more in our molecular pathology coding guide or see how we handle molecular diagnostics billing.
Drug testing splits into presumptive and definitive. Presumptive tests tell you a drug class may be present. Definitive tests identify and often quantify specific drugs.
Example: A pain management patient’s urine is screened by immunoassay on an analyzer, then confirmed by LC-MS/MS for nine drug classes. For Medicare, that’s 80307 plus G0481.
Specimen validity testing is included in the drug testing codes and isn’t billed separately. And blanket standing orders for every drug class on every visit are one of the fastest ways to fail a UDT audit. Our toxicology coding guide covers frequency and documentation in detail.
Surgical pathology codes (88300–88309) are assigned per specimen, and the level depends on the type of specimen, not on how hard the diagnosis was. A specimen is tissue that’s submitted for individual, separate attention, which usually means a separately labeled container.
Example: Three colon biopsies from three different sites, each in its own labeled jar, are three specimens. That’s 88305 × 3. Three biopsies dropped into one jar are one specimen: 88305 × 1.
Go deeper with our surgical pathology coding guide or our pathology lab billing page.
These three areas are where generalist billing companies leave the most money on the table, mostly through undercounted units.
Example: A leukemia/lymphoma panel with 20 markers is 88184 × 1, 88185 × 19, and 88189 for the pathologist’s interpretation. Billing 88185 × 1 because the panel is “one test” is a common and costly mistake. See our guide to FISH and flow cytometry coding and our oncology and hematopathology billing page.
Microbiology coding follows the workflow on the bench: culture, then identification, then susceptibility. Each step can be its own code, and units depend on how many organisms you actually worked up.
Example: A urine culture with colony count is 87086. Isolation and presumptive identification of the isolates is 87088. Susceptibility testing by microdilution on each isolate is 87186, one unit per organism tested.
Molecular infectious disease testing has its own range. Multiplex respiratory panels are coded by target count: 87631 (3–5 targets), 87632 (6–11) and 87633 (12–25). A combined SARS-CoV-2 and influenza A/B test is 87636, and 87637 adds RSV. Many payers now limit large syndromic panels to specific patient groups, so check the policy before you run 22 targets on an outpatient. Our microbiology coding guide has the full breakdown.
High volume, low price, and very easy to unbundle. The rule for panels is strict: you can report a panel code only when every listed component is performed. Add extra tests as separate lines. If one component is missing, code each test individually instead of the panel.
See the full rules in our clinical chemistry and hematology coding guide.
The ordering provider is responsible for documenting why a test is needed. The lab codes what’s on the order. It can translate a written description into the most specific ICD-10-CM code, but it can’t add a diagnosis the provider didn’t give. If the requisition is missing a diagnosis or the one provided doesn’t support the test, the fix is to go back to the provider before billing, not to choose a code that happens to pass the edit.
Two more rules that apply to outpatient lab coding:
Medicare decides coverage in two layers. National Coverage Determinations (NCDs) apply everywhere. Medicare has a set of lab NCDs that list covered, non-covered and frequency-limited diagnoses for common tests. Local Coverage Determinations (LCDs) are written by each Medicare Administrative Contractor (MAC) and apply only in its jurisdiction. The covered ICD-10 codes are usually published in a companion Billing and Coding Article.
That means the same test with the same diagnosis can be covered in one state and denied in another. If you’re not sure which MAC handles your claims, our Find Your MAC tool tells you in seconds, and our MAC jurisdictions page shows which LCDs apply.
When a test is likely to be denied as not medically necessary, Medicare expects the patient to be warned in advance with an Advance Beneficiary Notice of Noncoverage (form CMS-R-131). The ABN has to be signed before the specimen is collected or the service is performed. After that, the modifier on the claim tells Medicare what happened:
Reference labs often never meet the patient, so ABN collection has to happen at the draw site. Build that step into your client onboarding. Our guide to medical necessity for lab tests covers the full workflow, and our eligibility verification team checks coverage before the specimen is processed.
| Modifier | Meaning | When labs use it | Common mistake |
|---|---|---|---|
| 90 | Reference (outside) laboratory | The billing lab sent the test to another lab that performed it | Using it when payer rules require the performing lab to bill directly |
| 91 | Repeat clinical diagnostic lab test | The same test is repeated on the same day to get a new result, such as serial troponins | Using it for a rerun caused by a QC failure or instrument problem |
| 92 | Alternative laboratory platform testing | The test was run on a single-use, portable kit or device | Confusing it with QW |
| 59 / XE, XS, XP, XU | Distinct procedural service | Two codes that normally bundle were truly separate (different specimen, site or encounter) | Using it to push past an NCCI edit without documentation |
| QW | CLIA-waived test | Many CLIA-waived tests billed to Medicare | Leaving it off, or adding it to tests exempt from QW |
| 26 | Professional component | The pathologist bills only the interpretation | Billing 26 and global for the same service |
| TC | Technical component | The lab bills only the technical work | Billing TC on codes that have no TC split |
| GA / GZ / GX / GY | Liability and ABN status | Services expected to be denied or excluded | Appending GA without a signed, valid ABN |
| L1 | Separately payable hospital lab test | Hospital lab tests not packaged under OPPS | Missing it on qualifying outreach tests |
PTP edits pair codes that shouldn’t usually be billed together for the same patient on the same day. Each pair has a modifier indicator. An indicator of 0 means no modifier can unbundle the pair. An indicator of 1 means a modifier like 59 or XU can be used when the services were genuinely distinct and the record proves it. An indicator of 9 means the edit has been deleted.
An MUE is the maximum number of units of a code CMS expects for one patient on one date of service. Each MUE has an adjudication indicator (MAI):
Lab claims run into MUEs most often on 88305, IHC add-ons, flow cytometry markers and microbiology susceptibility codes. Splitting units across lines to dodge a date-of-service MUE doesn’t work and looks bad in an audit. Our guide to NCCI edits and MUEs for labs covers the scrubber rules that catch these before submission.
| CARC | What it means | Usual coding cause | First move |
|---|---|---|---|
| CO-4 | Code inconsistent with modifier, or a required modifier is missing | Missing QW, 26/TC, 90 or 91 | Correct and resubmit |
| CO-11 | Diagnosis inconsistent with the procedure | Diagnosis doesn't support the test, or a non-specific code was used | Check the order; get clarification from the provider |
| CO-16 | Claim lacks information or has submission errors | Missing ordering NPI, CLIA number or Z-Code | Add the missing data and resubmit |
| CO-50 | Not deemed medically necessary | Diagnosis not on the NCD/LCD covered list, or frequency exceeded | Review policy; appeal with records or bill the patient if a valid ABN exists |
| CO-97 | Included in payment for another service | Unbundled panel or PTP pair | Correct coding; appeal only if services were distinct |
| CO-151 | Information doesn't support this many services or this frequency | Units or frequency above payer limits | Review documentation; appeal if supported |
| CO-181 / CO-182 | Procedure code or modifier invalid on date of service | Deleted or not-yet-effective code after an annual update | Update the CDM and resubmit |
| CO-236 | Procedure or modifier combination not compatible under NCCI | PTP edit hit without a valid modifier | Correct coding, or add modifier with documentation |
| CO-B7 | Provider not certified or eligible for this service on this date | CLIA certificate type or dates don't match the test | Fix CLIA or enrollment data, then reprocess |
The pattern matters more than any single denial. If CO-11 keeps showing up for one client’s draws, the problem is the requisition, not the appeal letter. Our Laboratory Claims Denial Index breaks down where lab denials actually come from, and our guide to lab coding denials has a fix path for each CARC. When appeals are the right move, our denial management team handles them end to end.
January 1, 2027 is a big date for labs, for two reasons.
First, the code sets change: The 2027 CPT code set takes effect on January 1, with new, revised and deleted codes across the lab section. PLA codes keep arriving every quarter. The FY2027 ICD-10-CM update already took effect on October 1, 2026. Any code your CDM, LIS or scrubber still carries after its deletion date will come back as CO-181.
Second, Medicare lab rates are being reset: On September 21, 2026, CMS released preliminary CY2027 CLFS rates based on the latest PAMA private payor data. Forvis Mazars reported that 1,171 of roughly 1,500 test codes showed weighted medians below current 2026 payments. Under current law, the Consolidated Appropriations Act, 2026 limits any reduction to 15% per test per year for 2027 through 2029. The RESULTS Act would freeze rates and cap future cuts at 5% per year, but it had not passed as of this writing. Check the current status before you budget.
Before January, run through this short list:
We track these changes in our 2027 lab coding updates guide.
Good coding isn’t a person. It’s a system. The labs with the cleanest claims have the same five pieces in place.
If you want a place to start, our lab coding audit checklist gives you 25 checks to run before a payer runs them for you.
Plenty of labs code well in-house. It usually works when you have a stable test menu, certified coders who know your specialty, and the time to keep up with quarterly PLA releases, MolDX changes and LCD revisions.
It gets harder when the menu grows faster than the team. Adding molecular, tox or flow cytometry to a clinical lab brings a new set of rules overnight, and a coder who’s excellent at chemistry panels may not know that flow markers are billed per unit.
That’s the gap TransLabs was built to fill. We work only with laboratories. Our AAPC- and AHIMA-certified coders handle molecular tier codes, FISH, flow cytometry, cytogenetics, anatomic pathology, toxicology and microbiology every day, and our clients see a 98% first-pass clean claim rate. You get a dedicated specialist, not a shared queue, and there are no long-term contracts or upfront fees.